How apixaban works in Asian patients with atrial fibrillation
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at how the blood thinner apixaban (Eliquis) works in Asian patients with atrial fibrillation. By understanding how the drug is processed by the body, doctors may be able to personalize dosing for better safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with atrial fibrillation (an irregular heartbeat).
- You are taking apixaban (Eliquis) at a dose of 2.5 mg or 5 mg twice daily for at least 3 days.
- You are not on dialysis for kidney failure.
- You have not had a sudden kidney injury in the past 3 months.
- You do not have severe liver disease (Child-Pugh class C).
- You are not taking certain interacting medications (such as ketoconazole, rifampicin, or St. John's Wort), except amiodarone, verapamil, or diltiazem are allowed.
- You do not have a condition that significantly affects drug absorption (like short bowel syndrome).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This trial tests how well patients with atrial fibrillation take their apixaban medication and whether it is safe. It aims to see if using apixaban for the first time works well without causing bleeding problems.
This study tests whether a smartphone app that teaches patients about their blood thinner (apixaban, also called Eliquis) helps them take it more regularly. If you have atrial fibrillation and take apixaban, this app might help you manage your medication better.
This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.
This trial tests whether apixaban, a blood thinner, works well for people with atrial fibrillation who also have heart or circulation conditions. It uses a smartphone app to help track your treatment.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
Hear when a new Non Valvular Atrial Fibrillation (nv AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.